Skip to main content

Diabetes — Perioperative Management

Diabetes is present in ~20% of patients undergoing major general surgery, with another 23–60% harboring prediabetes or undiagnosed diabetes.[1] For the reconstructive urologist, two consequences matter above all others: hyperglycemia roughly triples SSI risk (and is the single most important modifiable risk factor for infection of a prosthetic implant — AUS, IPP, mesh sling), and uncontrolled diabetes independently predicts wound-healing failure, delirium, and prolonged LOS.[2][3] This article covers the 2026 ADA perioperative standards, the evidence behind the glycemic targets, and the specific medication-hold decisions that the urology service has to make the day before surgery.

See also: Cardiovascular Risk, ERAS, Wound Healing.

Why Glucose Control Matters in GU Reconstruction​

  • SSI — blood glucose >220 mg/dL on POD 1 predicts postoperative infection with 87.5% sensitivity; diabetics have 2.7-fold infection rates, 5.7-fold serious-infection rates.[2][3]
  • Prosthetic infection — HbA1c is the single most modifiable risk factor for artificial urinary sphincter and inflatable penile prosthesis infection. Most prosthetic-urology societies consider A1c >8.5% a relative contraindication to elective implantation.
  • Wound healing — hyperglycemia impairs collagen cross-linking, fibroblast function, and neutrophil chemotaxis.
  • Anastomotic healing — diabetes is an independent risk factor for vesicourethral anastomotic breakdown and ureteral reimplant stricture.
  • Perioperative MACE — diabetes is one of the six RCRI variables; insulin-dependence specifically scores a point.

Intensive perioperative glycemic-control protocols reduce SSI by roughly 57% (OR 0.43) in meta-analysis.[3][5]

Preoperative Targets (2026 ADA)​

HbA1c / Glucose Management Indicator​

  • Target A1c <8% (64 mmol/mol) within 3 months of elective surgery, with individualized risk-to-benefit assessment.[1]
  • Alternatively, 14-day GMI <8% and/or time-in-range >50% from CGM data.
  • Do NOT postpone elective surgery on A1c alone — the ADA explicitly cautions against denying needed surgery based on A1c in isolation.[1]

Who Needs Tighter Preoperative Optimization​

  • Elective prosthetic urologic surgery (AUS, IPP, sling, transvaginal mesh) — most urology societies aim for A1c <7–7.5% before implantation and defer non-emergent cases with A1c >8.5%.
  • Major reconstructive operations with bowel use (cystectomy with diversion, augmentation cystoplasty) — A1c <8% is a reasonable target given the combined infection/anastomotic-leak profile.
  • Urgent cancer cases — do not delay; optimize intraoperatively and postoperatively.

Perioperative Glycemic Targets​

SettingTargetReference
Critically ill / ICU140–180 mg/dL once insulin started[1][4]
Non-critically ill100–180 mg/dL[1]
Pre-, intra-, and postoperative100–180 mg/dL[1]

Do not target stricter ranges. The NICE-SUGAR trial (6,104 ICU patients) showed intensive control (80–110 mg/dL) produced:[4]

  • No mortality benefit, and in fact slightly higher mortality (27.5% vs 25%) vs conventional control.
  • 10–15× higher rate of severe hypoglycemia.

A 2023 Cochrane review confirmed intensive control gives little or no mortality difference, a possible but uncertain reduction in cardiovascular events, and a RR 4.73 for severe hypoglycemia.[2]

The net result: the pendulum has definitively swung away from tight control. 140–180 is the operational target for the sick; 100–180 for the floor.

Insulin Therapy​

Regimen Principles[1]​

  • Insulin is the only recommended glucose-lowering therapy in the perioperative period. All other classes are held.
  • Basal-bolus (basal + premeal short/rapid-acting) outperforms correction-only (sliding-scale) regimens for inpatient glycemic outcomes — use basal-bolus when the patient is eating.
  • Sole use of sliding-scale insulin without basal is discouraged.
  • Continuous IV insulin infusion is the preferred regimen for critically ill patients.

Dose Adjustments the Night Before Surgery[1][6]​

InsulinPreop adjustment
Long-acting basal (glargine, detemir, degludec)75–80% of usual dose the evening before
NPH (intermediate)50% of usual dose
Prandial / rapid-actingHold while NPO

25% basal dose reduction is associated with achieving perioperative glucose targets with a lower hypoglycemia rate. Individualize in T1DM — some patients require full basal to avoid DKA.

Morning of Surgery​

  • Hold prandial / rapid-acting insulin.
  • Continue adjusted basal (75–80% long-acting, 50% NPH).
  • Check POC glucose on arrival.
  • Start IV insulin infusion if NPO for >24 h, critically ill, on steroids, or with glucose >180 mg/dL that won't correct with subcutaneous.

By Clinical Setting[8]​

Type 1 diabetes or insulin-dependent type 2:

Eating statusPlan
EatingContinue outpatient basal ± prandial (consider 25–50% dose reduction) + correction
NPOContinue basal alone (hold prandial; consider 20–25% basal reduction) + correction

Type 2 diabetes, not on insulin:

Eating statusPlan
EatingStop non-insulin agents; start correction (sliding-scale) if well-controlled
NPOStop non-insulin agents; start correction
Poorly controlled (glucose ≥180 or A1c >10%)Start weight-based basal + prandial + correction

Non-Insulin Medications​

Metformin​

  • Hold on day of surgery.
  • The 2024 AHA/ACC guideline permits perioperative continuation (Class IIa) — the theoretical lactic-acidosis risk is not well-supported by modern data.[7]
  • Hold 24–48 h before and after any contrast study that may transiently reduce GFR.

Sulfonylureas (Glipizide, Glyburide, Glimepiride)​

  • Hold on the day of surgery — hypoglycemia risk while NPO.

SGLT2 Inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin)​

  • Hold 3 days before elective surgery (4 days for ertugliflozin).[1][9]
  • Mechanism for timing: half-lives and the risk window for euglycemic DKA — a documented perioperative emergency where DKA occurs with normal or near-normal glucose.
  • Restart postoperatively once stable, eating, not acidotic, and not receiving IV dextrose infusion.

GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Tirzepatide, Dulaglutide)​

A clinical hot topic. The 2023 ASA guidance suggested holding weekly GLP-1s a week before surgery and daily agents on the day of surgery due to delayed gastric emptying and aspiration risk.[1][7] The 2026 ADA advises a personalized approach:

  • No GI symptoms, low-risk surgery: may continue.
  • Active GI symptoms (nausea, vomiting, dyspepsia, early satiety): full stomach precautions (RSI, consider delaying).
  • Preoperative gastric ultrasound may be considered in high-risk cases.
  • Liquid diet for 24 h prior is an emerging mitigation strategy, particularly for elective endoscopic procedures and patients who cannot hold the drug.
  • Implement alternative glycemic management (insulin) if the agent is held and glycemia worsens.

DPP-4 Inhibitors (Sitagliptin, Linagliptin)​

  • May continue; low hypoglycemia risk.

Thiazolidinediones (Pioglitazone)​

  • Hold on day of surgery — fluid retention.

Glucose Monitoring​

  • POC glucose every 2–4 hours while NPO, intraoperatively, and postoperatively until stable.[1]
  • CGM cannot be used alone for surgical glucose monitoring — confirmatory POC required before insulin dosing.
  • Validation benchmarks: CGM within ±20% of POC when glucose ≥70 mg/dL, or ±20 mg/dL when <70.[1]

Insulin Pumps and Automated Insulin Delivery​

Pumps may be continued intraoperatively if institutional policy allows.[1][10]

  • Patient must be able to self-manage (or have a support person present).
  • Adequate supplies and trained staff.
  • Contraindications: impaired consciousness, critical illness, DKA/HHS, inability to adjust settings.
  • If the pump must come off: transition to IV insulin infusion or basal + correction subcutaneous.

Automated insulin delivery (hybrid closed-loop) systems — may continue if CGM and pump function are preserved; revert to manual mode if CGM fails.

Special Situations​

Steroid-Induced Hyperglycemia​

Perioperative steroids (adrenal-insufficiency stress dosing, dexamethasone antiemesis, chronic prednisone) drive predictable hyperglycemia peaking 4–8 h after dosing.[8]

  • NPH insulin at the time of the steroid dose: 0.1 U/kg/day per 10 mg prednisone equivalent.
  • Continuous glucocorticoid → continuous insulin; bolus steroid → matched-peak NPH.

Enteric Feeding​

  • Start weight-based basal + correction insulin.
  • Check glucose every 6 h.
  • Match basal profile to feed schedule (24 h continuous → long-acting basal; bolus feeds → NPH or premixed at each feed).

Total Parenteral Nutrition​

  • Add regular insulin directly to the TPN bag — approximately 1 U per 10 g dextrose.
  • Covers ~90% of insulin requirement.
  • Add subcutaneous correction insulin for residual glucose excursions.

Diabetic Ketoacidosis in the Surgical Patient​

Can occur postoperatively in T1DM with inadequate basal coverage, or euglycemic DKA with SGLT2 inhibitor continuation through surgery.

Diagnostic triad:[1][11]

  • Hyperglycemia (or euglycemia if SGLT2i)
  • Ketosis (ketonemia or ketonuria)
  • Metabolic acidosis (pH <7.30 or bicarbonate <18)

Management sequence:[11]

  1. Fluids first — 1 L 0.9% saline in the first hour for adults; then volume-status-adjusted.
  2. Insulin — IV regular 0.1 U/kg/h starting 1–2 h after fluids; drop to 0.05 U/kg/h once glucose reaches 250 mg/dL.
  3. Potassium — replete when K <5.2 mEq/L; hold insulin if K <3.3 until corrected.
  4. Bicarbonate — only if pH <6.9.
  5. Add dextrose to the fluid when glucose reaches 200–250 mg/dL to maintain insulin infusion until ketosis clears.
  6. Transition to subcutaneous basal-bolus only when anion gap has closed and the patient is eating.

GU-Reconstruction–Specific Considerations​

Prosthetic Urology — AUS, IPP, Sling​

A1c is the single most actionable preoperative variable for prosthetic-infection prevention.

  • Target A1c <7–7.5% before elective implantation.
  • Defer non-urgent implantation for A1c >8.5% and optimize.
  • Perioperative glycemic target <180 mg/dL intraoperatively and for 48 h postoperatively is standard.
  • Specific antibiotic bundles (vancomycin + gentamicin or equivalent) are standard for prosthetic urology regardless of diabetes status — but the combined infection risk in a poorly controlled diabetic is compounding.

Urinary Diversion (Cystectomy + Ileal Conduit / Neobladder)​

  • Bowel prep day + NPO + insulin-dependent diabetic is a high-hypoglycemia-risk setting — hold oral agents, reduce basal, maintain IV dextrose if needed.
  • Return-of-feeding gap (typical 3–5 d for open, earlier for MIS) — plan for IV insulin infusion bridging this window in insulin-dependent patients.
  • Metabolic acidosis from ileal diversion can worsen any underlying diabetic ketogenesis — monitor bicarbonate.

Neurogenic / Diabetic Bladder Dysfunction​

  • Diabetes autonomic neuropathy causes detrusor hypocontractility, impaired bladder sensation, and chronic urinary retention — relevant in the preoperative history for any patient presenting with incontinence or voiding dysfunction.
  • Post-obstructive diuresis after relief of diabetic neurogenic retention can cause profound electrolyte and glycemic shifts.

Renal Function​

Many long-standing diabetics have diabetic nephropathy. This affects:

  • DOAC dose selection.
  • Metformin continuation and contrast loading.
  • Gentamicin and aminoglycoside dosing for prosthetic prophylaxis.
  • ERAS fluid-balance decisions.

Summary of Key Recommendations​

RecommendationEvidence
Preoperative A1c <8% target within 3 months of elective surgery (individualize)ADA C
Perioperative glucose target 100–180 mg/dL (floor), 140–180 (ICU)ADA A / E
Basal-bolus insulin, not sliding-scale alone, in the inpatientADA A
Do NOT use tight glycemic control (80–110) — NICE-SUGAR / CochraneA
Hold SGLT2 inhibitors 3–4 days before surgeryADA / ACC Class I C-LD
Personalized hold strategy for GLP-1 receptor agonistsExpert consensus
Metformin may be continued or held on day of surgeryACC Class IIa C-LD
Reduce basal insulin to 75–80% (long-acting) or 50% (NPH) the evening before surgeryADA C
CGM cannot be used alone during surgeryADA E
Insulin pumps may continue with institutional supportADA C

References​

1. American Diabetes Association Professional Practice Committee. "16. Diabetes Care in the Hospital: Standards of Care in Diabetes — 2026." Diabetes Care. 2026;49(Suppl_1):S339–S355. doi:10.2337/dc26-S016

2. Bellon F, Solà I, Gimenez-Perez G, et al. "Perioperative Glycaemic Control for People With Diabetes Undergoing Surgery." Cochrane Database Syst Rev. 2023;8:CD007315. doi:10.1002/14651858.CD007315.pub3

3. Allegranzi B, Zayed B, Bischoff P, et al. "New WHO Recommendations on Intraoperative and Postoperative Measures for Surgical Site Infection Prevention." Lancet Infect Dis. 2016;16(12):e288–e303. doi:10.1016/S1473-3099(16)30402-9

4. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. "Intensive Versus Conventional Glucose Control in Critically Ill Patients." N Engl J Med. 2009;360(13):1283–97. doi:10.1056/NEJMoa0810625

5. de Vries FE, Gans SL, Solomkin JS, et al. "Meta-Analysis of Lower Perioperative Blood Glucose Target Levels for Reduction of Surgical-Site Infection." Br J Surg. 2017;104(2):e95–e105. doi:10.1002/bjs.10424

6. Sathya B, Davis R, Taveira T, Whitlatch H, Wu WC. "Intensity of Peri-Operative Glycemic Control and Postoperative Outcomes in Patients With Diabetes: A Meta-Analysis." Diabetes Res Clin Pract. 2013;102(1):8–15. doi:10.1016/j.diabres.2013.05.003

7. Thompson A, Fleischmann KE, Smilowitz NR, et al. "2024 AHA/ACC Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery." J Am Coll Cardiol. 2024;84(19):1869–1969. doi:10.1016/j.jacc.2024.06.013

8. Gauer RL, Abellada A, Stewart M, Kozloski R. "Managing Selected Chronic Conditions in Hospitalized Patients." Am Fam Physician. 2024;109(2):134–142.

9. Winchester DE, Mehta JJ, Alexander JT. "Perioperative Cardiovascular Medication Management for Noncardiac Surgery." JAMA. 2026. doi:10.1001/jama.2026.0067

10. Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. "Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings — Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2022;107(8):2101–2128. doi:10.1210/clinem/dgac278

11. Veauthier B, Levy-Grau B. "Diabetic Ketoacidosis: Evaluation and Treatment." Am Fam Physician. 2024;110(5):476–486.